Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).
about
Efficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysisActions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Medical management of overactive bladderCurrent pharmacotherapeutic strategies for overactive bladder.An overview of the clinical use of antimuscarinics in the treatment of overactive bladderPharmacodynamics of propiverine and three of its main metabolites on detrusor contractionEfficacy and safety of propiverine in children with overactive bladder.Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.Novel insights into renal D-amino acid oxidase accumulation: propiverine changes DAAO localization and peroxisomal size in vivo.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.The medical treatment of overactive bladder, including current and future treatments.Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.Pharmacotherapy for Pediatric Neurogenic Bladder.Spontaneously Occurring Formation of Intranuclear and Cytoplasmic Inclusions in Renal Proximal Epithelium Due to Accumulation of D-Amino Acid Oxidase in Wistar Hannover Rats.Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats.Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats.Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.Excitatory effect of propiverine hydrochloride on urethral activity in rats.Desmopressin alone versus desmopressin and an anticholinergic in the first-line treatment of primary monosymptomatic nocturnal enuresis: a multicenter study.Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study.Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms.Pediatric overactive bladder and lower urinary tract dysfunctions: diagnosis and treatment
P2860
Q28067504-5715C5A3-B07F-4EDF-8076-95AB2FAA48A3Q30483622-A7C4C087-C145-4E74-B7F7-F5C5C34ACA18Q33515909-3756F31E-3096-4314-A9FB-55EB13CEE945Q34124065-C1C4D988-D156-4428-BA36-9810E22AAB2AQ34706864-C716B4A8-B3FA-4B06-B7D7-E968ED3316FCQ35042575-26827F49-513B-4C7B-8A57-E5F5318074A6Q35048983-932C351E-A408-4BAF-B00E-400763CCA1D0Q35903871-E3687364-094E-4FB6-ACAA-34AFCA95704FQ35925548-E0371997-2F40-4E7F-B04C-32D5D95799A7Q35951912-9B02BB36-1FE4-4123-9F46-38C8A1C4EC52Q36428481-94916FD5-6309-4BBC-B04E-59EBD3DE90FCQ37836943-C32671BE-BFAE-4142-B00B-FF620258B2DDQ38071594-C7804624-1E32-4934-BB26-C03AB37EDC0EQ39437361-69065845-6E18-4C17-8A24-84DFA6EDE082Q41675433-36055E4D-E6AE-47A1-A6A6-FF62E08FA8BDQ43225326-C861B872-871D-4F94-A84B-19C5B2A743FBQ46816221-58758960-96E5-4C52-989F-A2A2BCB9C05FQ46862655-E2FDF008-FF25-4D84-BB31-87BC28144E54Q46906921-00EB6840-7EEE-4CF4-8F8E-9104029E2A28Q48182944-1E60A262-69E5-412F-930E-57D124E7E7BAQ51164731-DC78A6B8-8893-4433-8918-9DE384514647Q51373576-DE399CD2-F387-4637-92F5-01F99413F49AQ51484228-F704892B-84FB-43A3-8C9E-67B4EB653EAFQ54543594-B9FE9021-C455-4703-9506-381E5FD9B195Q57261042-D2F3A1DB-F0DA-4163-B0E8-059C7C30F045
P2860
Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@ast
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@en
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@nl
type
label
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@ast
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@en
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@nl
prefLabel
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@ast
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@en
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@nl
P356
P1476
Efficacy, tolerability and saf ...... on-neurogenic and neurogenic).
@en
P2093
Madersbacher H
P2888
P304
P356
10.1007/S003450100223
P577
2001-11-01T00:00:00Z
P6179
1039727405